pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search

calendar

20,516 catalysts · 4,728 grant · 3,706 8k filing · 2,933 device 510k · 2,761 approval · 2,000 device pma · 2,000 device recall

★ save view↓export CSV
next 91 dayslessmore
MonWedFri
2026-08-31: 0 catalysts2026-09-01: 0 catalysts2026-09-02: 0 catalysts2026-09-03: 0 catalysts2026-09-04: 6 catalysts2026-09-05: 0 catalysts2026-09-06: 0 catalysts2026-09-07: 0 catalysts2026-09-08: 0 catalysts2026-09-09: 0 catalysts2026-09-10: 0 catalysts2026-09-11: 0 catalysts2026-09-12: 0 catalysts2026-09-13: 0 catalysts2026-09-14: 0 catalysts2026-09-15: 0 catalysts2026-09-16: 0 catalysts2026-09-17: 0 catalysts2026-09-18: 0 catalysts2026-09-19: 0 catalysts2026-09-20: 0 catalysts2026-09-21: 0 catalysts2026-09-22: 0 catalysts2026-09-23: 2 catalysts2026-09-24: 0 catalysts2026-09-25: 0 catalysts2026-09-26: 0 catalysts2026-09-27: 0 catalysts2026-09-28: 0 catalysts2026-09-29: 0 catalysts2026-09-30: 1 catalyst2026-10-01: 0 catalysts2026-10-02: 0 catalysts2026-10-03: 0 catalysts2026-10-04: 0 catalysts2026-10-05: 0 catalysts2026-10-06: 0 catalysts2026-10-07: 0 catalysts2026-10-08: 2 catalysts2026-10-09: 0 catalysts2026-10-10: 0 catalysts2026-10-11: 0 catalysts2026-10-12: 0 catalysts2026-10-13: 1 catalyst2026-10-14: 1 catalyst2026-10-15: 0 catalysts2026-10-16: 0 catalysts2026-10-17: 0 catalysts2026-10-18: 0 catalysts2026-10-19: 1 catalyst2026-10-20: 2 catalysts2026-10-21: 2 catalysts2026-10-22: 2 catalysts2026-10-23: 1 catalyst2026-10-24: 0 catalysts2026-10-25: 0 catalysts2026-10-26: 1 catalyst2026-10-27: 8 catalysts2026-10-28: 12 catalysts2026-10-29: 21 catalysts2026-10-30: 4 catalysts2026-10-31: 0 catalysts2026-11-01: 0 catalysts2026-11-02: 9 catalysts2026-11-03: 18 catalysts2026-11-04: 22 catalysts2026-11-05: 37 catalysts2026-11-06: 2 catalysts2026-11-07: 0 catalysts2026-11-08: 0 catalysts2026-11-09: 1 catalyst2026-11-10: 0 catalysts2026-11-11: 0 catalysts2026-11-12: 0 catalysts2026-11-13: 0 catalysts2026-11-14: 0 catalysts2026-11-15: 0 catalysts2026-11-16: 0 catalysts2026-11-17: 0 catalysts2026-11-18: 0 catalysts2026-11-19: 0 catalysts2026-11-20: 0 catalysts2026-11-21: 0 catalysts2026-11-22: 0 catalysts2026-11-23: 0 catalysts2026-11-24: 0 catalysts2026-11-25: 0 catalysts2026-11-26: 0 catalysts2026-11-27: 0 catalysts2026-11-28: 0 catalysts2026-11-29: 0 catalysts
view
agendamonth
sort
soonestlatesttypesponsoralpha
from 2025-05-19×clear all
type
  • grant4,728
  • 8k filing3,706
  • device 510k2,933
  • approval2,761
  • device pma2,000
  • device recall2,000
  • device adverse event1,000
  • recall723
  • earnings585
  • phase 2 completion172
  • therapy area
    • Oncology148
    • Infectious Disease46
    • Cardiology37
    • Immunology35
    • Dermatology31
    • Pulmonology22
    • Women's Health19
    • Ophthalmology16
    • Pain15

    Week of Apr 27, 2026

    50
    ›Apr 28, 2026phase iv trial initiation130d agoRajendra Institute of Medical Sciences — levobupivacaine (Phase IV Trial Initiation)levobupivacaine

    Therapy area: Central Nervous System. Indication: Pain

    full page →levobupivacaine →source: globaldata
    ›Apr 28, 20268k filing130d ago$JNJ — JOHNSON & JOHNSON (JNJ) — 8-K filing

    Items: 5.07, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing130d ago$GNPX — Genprex, Inc. (GNPX) — 8-K filing

    Items: 8.01, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing130d ago$PASG — Passage BIO, Inc. (PASG) — 8-K filing

    Items: 2.05

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing130d ago$ACRS — Aclaris Therapeutics, Inc. (ACRS) — 8-K filing

    Items: 7.01, 8.01, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing130d ago$INCY — INCYTE CORP (INCY) — 8-K filing

    Items: 2.02

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing130d ago$AVTX — Avalo Therapeutics, Inc. (AVTX) — 8-K filing

    Items: 1.01, 7.01, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing130d ago$IMUX — IMMUNIC, INC. (IMUX) — 8-K filing

    Items: 5.02, 7.01, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing130d ago$SGMT — Sagimet Biosciences Inc. (SGMT) — 8-K filing

    Items: 1.01, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing130d ago$ELAB — PMGC Holdings Inc. (ELAB) — 8-K filing

    Items: 7.01, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing130d ago$KNSA — Kiniksa Pharmaceuticals International, plc (KNSA) — 8-K filing

    Items: 2.02, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing130d ago$WVE — Wave Life Sciences Ltd. (WVE) — 8-K filing

    Items: 2.02, 7.01, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing130d agoROCKET PHARMACEUTICALS, INC. (RCKT, RCKTW) — 8-K filing

    Items: 1.01, 7.01, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing130d ago$SNGX — SOLIGENIX, INC. (SNGX) — 8-K filing

    Items: 8.01, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing130d ago$BCDA — BioCardia, Inc. (BCDA) — 8-K filing

    Items: 8.01, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing130d ago$ALLR — Allarity Therapeutics, Inc. (ALLR) — 8-K filing

    Items: 8.01, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing130d agoSilexion Therapeutics Corp (SLXN, SLXNW) — 8-K filing

    Items: 7.01, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing130d ago$BMEA — Biomea Fusion, Inc. (BMEA) — 8-K filing

    Items: 7.01, 8.01, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing130d ago$ARAY — ACCURAY INC (ARAY) — 8-K filing

    Items: 5.02, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing130d ago$CLYM — Climb Bio, Inc. (CLYM) — 8-K filing

    Items: 1.01, 3.02, 8.01, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing130d ago$GILD — GILEAD SCIENCES, INC. (GILD) — 8-K filing

    Items: 7.01, 8.01, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing130d ago$ACET — Adicet Bio, Inc. (ACET) — 8-K filing

    Items: 3.02, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing130d ago$NRC — NRC HEALTH (NRC) — 8-K filing

    Items: 2.02, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing130d ago$ACLX — Arcellx, Inc. (ACLX) — 8-K filing

    Items: 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing130d ago$DSGN — Design Therapeutics, Inc. (DSGN) — 8-K filing

    Items: 2.02, 7.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing130d ago$NRC — NRC HEALTH (NRC) — 8-K filing

    Items: 5.02

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing130d ago$OPK — OPKO HEALTH, INC. (OPK) — 8-K filing

    Items: 2.02, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing130d ago$VTGN — Vistagen Therapeutics, Inc. (VTGN) — 8-K filing

    Items: 8.01, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing130d ago$LABT — Lakewood-Amedex Biotherapeutics Inc. (LABT) — 8-K filing

    Items: 5.02, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing130d agoSeaStar Medical Holding Corp (ICU, ICUCW) — 8-K filing

    Items: 8.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing130d ago$FLNA — FILANA THERAPEUTICS, INC. (FLNA) — 8-K filing

    Items: 5.02

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing130d ago$PTCT — PTC THERAPEUTICS, INC. (PTCT) — 8-K filing

    Items: 7.01, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing130d ago$HRGN — Harvard Apparatus Regenerative Technology, Inc. (HRGN) — 8-K filing

    Items: 7.01, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing130d ago$MDGL — MADRIGAL PHARMACEUTICALS, INC. (MDGL) — 8-K filing

    Items: 5.02

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing130d ago$FENC — FENNEC PHARMACEUTICALS INC. (FENC) — 8-K filing

    Items: 5.02

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing130d ago$QNCX — Quince Therapeutics, Inc. (QNCX) — 8-K filing

    Items: 8.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing130d ago$PREM — Premier Air Charter Holdings Inc. (PREM) — 8-K filing

    Items: 2.02, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing130d agoScilex Holding Co (SCLX, SCLXW) — 8-K filing

    Items: 1.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing130d ago$JANX — Janux Therapeutics, Inc. (JANX) — 8-K filing

    Items: 5.02

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing130d ago$CTOR — CITIUS ONCOLOGY, INC. (CTOR) — 8-K filing

    Items: 3.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing130d ago$QUCY — Quantum Cyber N.V. (QUCY) — 8-K filing

    Items: 1.01, 3.02, 5.01, 5.02, 5.03, 5.07, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing130d ago$GRDX — GridAI Technologies Corp. (GRDX) — 8-K filing

    Items: 3.01, 7.01, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing130d ago$LNAI — Lunai Bioworks Inc. (LNAI) — 8-K filing

    Items: 8.01, 9.01

    full page →edgar 8k ↗
    ›Apr 29, 2026pdufa129d agoSanofi — teplizumab (PDUFA)teplizumab

    Therapy area: Metabolic Disorders. Indication: Type 1 Diabetes (Juvenile Diabetes)

    full page →teplizumab →source: globaldata
    ›Apr 29, 2026phase 0 trial completion129d agoDana-Farber Cancer Institute Inc — atezolizumab (Phase 0 Trial Completion)atezolizumab

    Therapy area: Oncology. Indication: Hepatocellular Carcinoma, Liver Cancer

    full page →atezolizumab →source: globaldata
    ›Apr 29, 2026phase 1 completion129d agoBoehringer Ingelheim International GmbH — BI-765179 (Phase I Trial Completion)BI-765179

    Therapy area: Oncology. Indication: Cervical Cancer, Colorectal Cancer, Cutaneous Squamous Cell Carcinoma (cSCC), Esophageal Cancer, Esophageal Squamous Cell Carcinoma (ESCC), Gastric Cancer, Head And Neck Cancer, Head And Neck Squamous Cell Carcinoma (HNSC), Hepatocellular Carcinoma, Hypopharyngeal Cancer, Laryngeal Cancer, Malignant Pleural Mesothelioma, Melanoma, Non-Small Cell Lung Carcinoma, Oral Cancer, Oral Cavity (Mouth) Cancer, Oropharyngeal Cancer, Ovarian Cancer, Pancreatic Cancer, Re

    full page →BI-765179 →source: globaldata
    ›Apr 29, 2026phase 1 completion129d agoUniversity of Washington — autologous mitochondria (Phase I Trial Completion)autologous mitochondria

    Therapy area: Cardiovascular. Indication: Cerebrovascular Disease, Ischemia

    full page →autologous mitochondria →source: globaldata
    ›Apr 29, 2026phase 1 completion129d agoAltasciences Co Inc — NN-7442 (Phase I Trial Completion)NN-7442

    Therapy area: Hematological Disorders. Indication: Hemophilia A (Factor VIII Deficiency)

    full page →NN-7442 →source: globaldata
    ›Apr 29, 2026phase 1 initiation129d agoTerSera Therapeutics LLC — goserelin LA (Phase I Trial Initiation)goserelin LA

    Therapy area: Oncology. Indication: Breast Cancer, Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer), Metastatic Breast Cancer

    full page →goserelin LA →source: globaldata
    ›Apr 29, 2026phase 1 initiation129d agoOcugen Inc — adenovirus vector (spike protein) vaccine (Phase I Trial Initiation)adenovirus vector (spike protein) vaccine

    Therapy area: Infectious Disease. Indication: Coronavirus Disease 2019 (COVID-19)

    full page →adenovirus vector (spike protein) vaccine →source: globaldata
    ← prev
    page 333 of 411
    next →
    $OCGN1.2800-2.29%
    $SNY44.33-0.31%